Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary - SynAct Pharma

Healthcare

Sparks - SynAct Pharma

More on this equity
SynAct Pharma (STO: SYNACT) initiates the Phase II RESOVIR-2 study in dengue
Published by Jyoti Prakash, CFA

SynAct Pharma has initiated patient dosing in the Phase II RESOVIR-2 study evaluating resomelagon as an add-on therapy targeting dengue-associated hyperinflammation, representing a further step in extending its host-directed, inflammation-resolution strategy into acute infectious settings (following the Phase II RESPIRE study initiation in viral respiratory insufficiency in January 2026). The study is a randomised, placebo-controlled trial (n=120; 1:1) assessing time to disease resolution and progression to severe dengue, with top-line data anticipated in Q326.

While resomelagon’s investment case remains anchored to the Phase IIb ADVANCE readout in rheumatoid arthritis (expected by mid-2026), we view RESOVIR-2 as a strategically relevant programme that broadens the therapeutic scope of its melanocortin-driven mechanism. The study builds on prior COVID-19 proof-of-concept data and offers incremental optionality in the medium term.

Next Sparks Commentary in this sector >

Latest

Industrials | Comment

Oerlikon (SIX: OERL) – materials strength drives FY26 guidance upgrade

TMT | Comment

Devolver Digital (LSE: DEVO): AIM cancellation proposed, with $5.0m tender offer attached

Industrials | Comment

Morgan Advanced Materials (LSE: MGAM) – Phasing lifts H126 margin

TMT | Comment

Pathos Communications (AIM: NEWS) – Record July revenue supports H126 trading update

Industrials | Comment

PVA TePla (FRA: PVE) – Q226 results
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.